Assessing the Impact of Long-term Inhaled Corticosteroid Therapy on Patients with COVID-19 and Coexisting Chronic Lung Disease: A Multicenter Retrospective Cohort Study

Background: Patients with chronic lung disease (CLD), such as asthma or chronic obstructive pulmonary disease, were expected to have an increased risk of clinical manifestations and severity of COVID-19. However, these comorbidities have been reported less frequently than expected. Chronic treatment with inhaled corticosteroids (ICS) may impact the clinical course of COVID-19. The main objective of this study is to know the influence of chronic treatment with ICS on the prognosis of COVID-19 hospitalized patients with CLD.

Methods: A multicenter retrospective cohort study was designed, including patients hospitalized with COVID-19. Epidemiological and clinical data were collected at admission and at seven days, and clinical outcomes were collected. Patients with CLD with and without chronic treatment with ICS were compared.

Results: Two thousand five hundred ninety-eight patients were included, of which 1,171 patients had a diagnosis of asthma and 1,427 of COPD (53.37% and 41.41% with ICS, respectively). No differences were found in mortality, transfer to ICU, or development of moderate-severe ARDS. Patients with chronic ICS had a longer hospital stay in both asthma and COPD patients (9 vs. 8 days, 0.031 in asthma patients), (11 vs. 9 days, 0.018 in COPD patients); although they also had more comorbidity burden.

Conclusions: Patients with chronic inhaled corticosteroids had longer hospital stays and more chronic comorbidities, measured by the Charlson comorbidity index, but they did not have more severe disease at admission, evaluated with qSOFA and PSI scores. Chronic treatment with inhaled corticosteroids had no influence on the prognosis of patients with chronic lung disease and COVID-19.

References

Singh D, Halpin D . Inhaled corticosteroids and COVID-19-related mortality: confounding or clarifying?. Lancet Respir Med. 2020; 8(11):1065-1066. PMC: 7515581. DOI: 10.1016/S2213-2600(20)30447-1. View

Perotin J, Adam D, Vella-Boucaud J, Delepine G, Sandu S, Jonvel A . Delay of airway epithelial wound repair in COPD is associated with airflow obstruction severity. Respir Res. 2014; 15:151. PMC: 4251925. DOI: 10.1186/s12931-014-0151-9. View

Weiss P, Murdoch D . Clinical course and mortality risk of severe COVID-19. Lancet. 2020; 395(10229):1014-1015. PMC: 7138151. DOI: 10.1016/S0140-6736(20)30633-4. View

Louis R, Calmes D, Frix A, Schleich F . [COVID-19 and asthma]. Rev Med Liege. 2020; 75(S1):130-132. View

Lippi G, Henry B . Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19). Respir Med. 2020; 167:105941. PMC: 7154502. DOI: 10.1016/j.rmed.2020.105941. View

Kermali M, Khalsa R, Pillai K, Ismail Z, Harky A . The role of biomarkers in diagnosis of COVID-19 - A systematic review. Life Sci. 2020; 254:117788. PMC: 7219356. DOI: 10.1016/j.lfs.2020.117788. View

Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Lian N . The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis. J Med Virol. 2020; 92(10):1915-1921. PMC: 7262275. DOI: 10.1002/jmv.25889. View

Baker J, Mahdi M, Nicolau Jr D, Ramakrishnan S, Barnes P, Simpson J . Early Th2 inflammation in the upper respiratory mucosa as a predictor of severe COVID-19 and modulation by early treatment with inhaled corticosteroids: a mechanistic analysis. Lancet Respir Med. 2022; 10(6):545-556. PMC: 8989397. DOI: 10.1016/S2213-2600(22)00002-9. View

Sen P, Majumdar U, Zein J, Hatipoglu U, Attaway A . Inhaled corticosteroids do not adversely impact outcomes in COVID-19 positive patients with COPD: An analysis of Cleveland Clinic's COVID-19 registry. PLoS One. 2021; 16(6):e0252576. PMC: 8174679. DOI: 10.1371/journal.pone.0252576. View

10.

Wu Z, McGoogan J . Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323(13):1239-1242. DOI: 10.1001/jama.2020.2648. View

11.

Kim E, Kim M, Lee J, Lee S, Lim S, Park J . Clinical Impact of the Bronchiectasis with Chronic Bronchitis Symptoms in COPD: Analysis of a Longitudinal Cohort. Int J Chron Obstruct Pulmon Dis. 2021; 16:2997-3008. PMC: 8570290. DOI: 10.2147/COPD.S332299. View

12.

Schultze A, Walker A, Mackenna B, Morton C, Bhaskaran K, Brown J . Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform. Lancet Respir Med. 2020; 8(11):1106-1120. PMC: 7515601. DOI: 10.1016/S2213-2600(20)30415-X. View

13.

Yamaya M, Nishimura H, Deng X, Sugawara M, Watanabe O, Nomura K . Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. Respir Investig. 2020; 58(3):155-168. PMC: 7102607. DOI: 10.1016/j.resinv.2019.12.005. View

14.

Kim V, Zhao H, Boriek A, Anzueto A, Soler X, Bhatt S . Persistent and Newly Developed Chronic Bronchitis Are Associated with Worse Outcomes in Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc. 2016; 13(7):1016-25. PMC: 5015750. DOI: 10.1513/AnnalsATS.201512-800OC. View

15.

Qiu H, Tong Z, Ma P, Hu M, Peng Z, Wu W . Intensive care during the coronavirus epidemic. Intensive Care Med. 2020; 46(4):576-578. PMC: 7080064. DOI: 10.1007/s00134-020-05966-y. View

16.

Matsuyama S, Kawase M, Nao N, Shirato K, Ujike M, Kamitani W . The Inhaled Steroid Ciclesonide Blocks SARS-CoV-2 RNA Replication by Targeting the Viral Replication-Transcription Complex in Cultured Cells. J Virol. 2020; 95(1). PMC: 7737752. DOI: 10.1128/JVI.01648-20. View

17.

Ramakrishnan S, Nicolau Jr D, Langford B, Mahdi M, Jeffers H, Mwasuku C . Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial. Lancet Respir Med. 2021; 9(7):763-772. PMC: 8040526. DOI: 10.1016/S2213-2600(21)00160-0. View

18.

Whittaker H, Jarvis D, Sheikh M, Kiddle S, Quint J . Inhaled corticosteroids and FEV decline in chronic obstructive pulmonary disease: a systematic review. Respir Res. 2019; 20(1):277. PMC: 6894275. DOI: 10.1186/s12931-019-1249-x. View

19.

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229):1054-1062. PMC: 7270627. DOI: 10.1016/S0140-6736(20)30566-3. View

20.

Gomez Antunez M, Muino Miguez A, Bendala Estrada A, Maestro de la Calle G, Monge Monge D, Boixeda R . Clinical Characteristics and Prognosis of COPD Patients Hospitalized with SARS-CoV-2. Int J Chron Obstruct Pulmon Dis. 2021; 15:3433-3445. PMC: 7801905. DOI: 10.2147/COPD.S276692. View